+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Rising Stars Outlook 2015

  • ID: 3106271
  • Report
  • January 2015
  • Region: Global, United States, India, Australia, Italy, Japan, South Korea
  • 72 Pages
  • MP Advisors
1 of 4


  • Bugworks
  • CESCA Therapeutics
  • Japan Tissue Engineering
  • Medipost
  • Mesobalst Ltd
  • Orgenesis
  • MORE
Innovative Therapies for treating diseases are highly sought after, as new discoveries are made in the field of biology. One area which is poised to bring about a seismic change in the way diseases are treated in the coming decades is the stem cell therapy/regenerative medicine space.

The number of companies researching and developing new products in this area have reached significant proportions, ensuring there is much to be aware of for those keeping pace with the development of new medicines. The regenerative medicine universe is ever-expanding, and new companies are constantly joining and brancing out into new areas. As a result, the authors have used some filters to select a few names for a detailed coverage in our Outlook this year.

Key Criteria for Selection:

- Uniqueness of the Technology platform and the ability to scale up commercially in case of positive outcome of products in the pipeline
- Pipeline and clinical data analysis
- Marketed product and commercial tie up. Robustness of the Management, financial and business model.

Note: Product cover images may vary from those shown
2 of 4


  • Bugworks
  • CESCA Therapeutics
  • Japan Tissue Engineering
  • Medipost
  • Mesobalst Ltd
  • Orgenesis
  • MORE
Part 1- Rising Stars in Regenerative Medicine and Stem cell based Cell Therapies-Drugs of the Future

Company Analysis:
CESCA Therapeutics Inc. : Hedging the Risk with Stem Cell Based Devices and Therapies and Global Presence
- Figure 1: Products In Pipeline
- Table 1: Clinical Development- Critical Limb Ischemia (ClI)Data Key Milestones
Ocata Therapeutics Inc: Ophthalmic Focus- Macular degenerative conditions- Looking with a New Eye
- Figure 1: Market For Age-Related Macular Degeneration (AMD)
- Figure 2: Products In The Pipeline
Orgenesis: Focus- Diabetes- Tricking your Liver to Make Insulin!
- Technology Platform
- Figure 1: Schematic Representation Of Making Autologous Insulin Producing (AIP) Cell
Tigenix NV : Exploiting the Adipose Tissue- Multiple Applications of Fat?
- Technology Platform
- Marketed Products
- Figure 1 : Products In Pipeline
- Key Milestones
Pluristem Therapeutics Inc: Regenerating and Recycling- Allogenic Therapies from the Placenta
- PluriX 3D Technology Platform
- Pipeline
- Figure 1 : Classification Of Peripheral Arterial Disease Types
- Market Opportunity
- Key Milestones
Mesoblast: Leader in Regenerative Sapce in Korea- Focusing on International Markets
- Technology Platform
- Pipeline- Focus on four major areas
- Figure 1: Drugs In The Pipeline
- Figure 2 : CHFf Discease Classification And Target Patients In PhIII Trial
- Figure 3: PhiII Data Of MPC-150 In CHF
- Figure 4 : Market Opportunity In Chronic Low Back Pain (CLBP)
- Key Milestones
Medipost Co Ltd : Leader in Regenerative Space in Korea- Focusing on International Markets
- Marketed and Products in the Pipeline
- Key Milestones
- Figure 1: Sales By Business Segment

JCR Pharmaceuticals co. Ltd.: First Stem Cell Based Product in Japan for Graft-Versus-Host Disease (GVHD).
- Technology Platform
- Product in the Pipeline
- Key Milestones
- Facts and Financials
- Table 1 : Pipeline Table
- Figure 1: Sales By Business Segments
Japan Tissue Engineering co. Ltd: Building Confidence in Regenerative Medicine- Fuji film Venture from Colors to Regenerative Medicine-
- Plat form Focus
- Products
- Figure 1 : Therapy and Product Focus

Part II-Indian Innovators- Rising Stars:
- Table 1: Select new generation innovation /drug discovery Indian companies
Connexios: Maturing Pipeline and Focus on Diabetes/Metabolic Disorders to Drive Visibility
- Technology Platform
- Therapy Focus—Diabetes/Metabolic Disorder and Non Alcoholic Steatohepatitis (NASH)
- Key Milestones
- Table 1: Differences Between G-Protein Coupled Receptor Agonists
- Table 2: Pipeline Of GPR Agonist For Treatment Of Type 2 Diabetes
- Figure 1: Products In Pipeline- Diabetes
- Figure 2: Products In Pipeline For NASH
- Figure 3: Other Programs
Cellworks : In silico Technology Platform Poised to Deliver- Focus on Personalised Medicine and Cancer
- Figure 1 : Simulation Based Personalized Medicine
- Figure 2 : Cellworks Therapeutic Programs
Bugworks: In silico Technology platform being applied to Serious Hospital Infections- Need of the hour!
- Therapy focus- Serious Hospital Infection
- Technology Platform
- Figure 1: Drug Development Success For TB
- Figure 2 : Going Way Froward
Tergene : Affordable and Second Generation Vaccines- Addressing the Urgent needs of Emerging Markets.
- Development Strategy and Status
- Figure 1: Sales Of Currently Available Vaccines For Streptococcus Pneumonia
- Figure 2: WW Demand Forecast Of Vaccines For Streptococcus Pneumonia
- Figure 3: Vaccine Market
Note: Product cover images may vary from those shown
3 of 4


4 of 4
- Bugworks
- CESCA Therapeutics
- Cellworks
- Connexios
- JCR Pharmaceuticals
- Japan Tissue Engineering
- Medipost
- Mesobalst
- Mesobalst Ltd
- OCATA Therapeutics
- Orgenesis
- Pluristem Therapeutics
- Tergene
- TiGenix
Note: Product cover images may vary from those shown